Raynovent Announces Positive Topline Results from Phase 2b Trial of ZSP1601 in Patients with Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Top-Line Analysis Data Results Obtained for Two Phase III Clinical Trials of Onradivir Granules (Pediatric) and Onradivir Tablets (Adolescent)!

Raynovent and Qilu Pharmaceutical Reach Strategic Cooperation Agreement to Jointly Advance Commercialization of RAY1225 in China Region!

2026 Year-Opening Success! RAY1225 Injection Efficiently Completes Enrollment Target in Phase III Clinical Trial for Monotherapy in Type 2 Diabetes

Double Victory! Onradivir Achieves Enrollment Completion in Two Pivotal Phase III Clinical Studies, Full-Age Protection on the Horizon!